Dedicated to infectious disease solutions transparency global health collaboration innovation success our clients
We are a clinical research organisation
driving infectious disease products
Who are we and what is our expertise?
We strongly believe that early phase clinical trials can be designed to provide critical proof-of-concept data faster and more cost-efficient. Without compromising on quality, the INFECTA team takes pride in designing fit-for-purpose early phase clinical trials which aim to maximally derisk your clinical development path.
We provide a wide range of services for the development of vaccines, therapeutics, antivirals and biologics. We use and develop various clinical research methodologies and hold the largest global portfolio of controlled human infection models (CHIMs).
Emerging from the longstanding collaboration between four Dutch University Medical Centers and the Centre for Human Drug Research (CHDR), we have a strong legacy in early phase clinical research programs and a solid scientific foundation, including decades of experience with CHIMs.
How can we support you?
We can become your trusted partner during the clinical development of your infectious diseases’ compounds. We can provide support with the following activities:
Early-phase clinical research
01
We are a full-service CRO with over thirty years of experience in healthy volunteer studies. We design your trial, draft the protocol and submission package, and guide it through the regulatory process according to the agreed timelines and standards…
Development of novel clinical research methodologies
02
We are internationally recognized for CHIM expertise. When appropriate and ethically approved, CHIMs can substantially accelerate infectious-disease product development by enabling early, decision-quality read-outs…
Laboratory support
03
INFECTA operates a fully equipped laboratory up to BSL-3 for sample processing. Safety, virology and bacteriology endpoint assays are performed in-house or via accredited partner labs…
Early-phase development & end-to-end consulting
04
Building on decades in early-phase development, we help map the path from candidate to first-in-human and beyond…
Why choose INFECTA
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam euismod libero a vulputate venenatis. Suspendisse nec tortor ultricies, rhoncus eros eget, dignissim dui. Phasellus commodo elit non lectus sodales, ac vulputate lacus placerat.
Globally largest CHIM portfolio
Capacity to produce, establish and validate new CHIMs
Not-for-profit base with focus on social impact
Large academic network
Our controlled human infection models repository
Controlled human infection models (CHIMs) are powerful tools that can be used to study host-pathogen interaction in specific infections, as well as test efficacy of novel therapeutics and vaccines. CHIMs enable a swift and cost-efficient assessment of drug safety and efficacy early in clinical development, derisking your future clinical development path.
With decades of experience in performing CHIMs, the INFECTA team will carefully balance risks and benefits of these models for your product and give you insights into what you can or cannot learn from them. The INFECTA team manages the regulatory and operational complexities of these studies, selects the pathogen and has protocols available for the exposure and clinical follow up of the volunteers. Endpoints can be clinical, microbiological and immunological. We can ensure the consistence and robustness of the trials.
We already have an extensive portfolio of CHIMs, and are continuing to develop more. All CHIMs are developed in collaboration with our academic partners.
Viruses
Our CHIMs support research across a range of respiratory and vector-borne viruses, such as Dengue & Influenza
Bacteria
Our repository of CHIMs including Bordetella Pertussis and Pneumococcus provides a valuable platform.
Parasites
With our CHIMs for parasites like Malaria & Hookworm, you can ensure that your process is sped-up
Our expertise lies in the pharmaceutical product development for infectious diseases with pandemic potential.
Company updates
Building the Future of C. difficile Research with a Human Infection Model
July 4, 2025
Clostridioides difficile (C. difficile) remains a major cause of healthcare-associated diarrhoea, with rising antibiotic resistance and frequent relapses making treatment increasingly difficult. While faecal…
Female-Only Schistosomiasis Infection Model Reveals Surprising Resistance
July 4, 2025
In this study schistosomiasis research is boosted by developing the first controlled human infection model using female-only Schistosoma mansoni parasites. This innovative approach aims…
Our new website is live
June 19, 2025
Genetically Attenuated Parasites Ushers In a New Era in Malaria Vaccination
June 19, 2025
Despite decades of effort, malaria remains a global health challenge, with current vaccines offering only modest and short-lived protection. This clinical trial brings fresh…